Rigrodsky & Long, P.A. Investigates HealthTronics, Inc. Merger

Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of HealthTronics, Inc. (“HealthTronics” or the “Company”) (Nasdaq:HTRN) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Endo Pharmaceuticals Holdings Inc. (“Endo”) (Nasdaq:ENDP) in a transaction valued at approximately $223 million (http://www.rigrodskylong.com/news/HTRN).

Under the proposed agreement, Endo will commence an all cash tender offer to acquire 100 percent of the outstanding shares of HealthTronics for approximately $223 million or $4.85 cash per HealthTronics share plus the assumption of approximately $35 million in net debt. HealthTronics shares that are not acquired in the tender offer will be purchased at the same price in a second-step merger. The investigation concerns whether HealthTronics’ board of directors failed to adequately shop the Company and obtain the best price possible for HealthTronics’ shareholders before entering into the agreement with Endo.

As recent as March 4, 2010, the Company reported its fourth quarter 2009 financial results and its guidance for 2010 wherein HealthTronics reported increased revenue from the same quarter in 2008. James Whittenburg, HealthTronics’ President and CEO, commented, “[o]ur Fourth Quarter and Year-End results mark excellent progress in our ability to successfully leverage our platform of unique relationships with over 2,500 urologists nationally.” HealthTronics also announced that “the Company’s 2010 guidance reflects continued reinvestment into growth initiatives that help position the Company for meaningful organic growth in 2011 and beyond.” Indeed, at least one analyst has set a price target of $7.00 per share for HealthTronics.

If you own the common stock of HealthTronics and purchased your shares before May 5, 2010, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky, Esquire or Noah R. Wortman, Case Development Director, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware, by telephone at [phone], or by e-mail to [e-mail].

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.